Oncology · 2009 · 27 citations · 0 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyOncology PharmacotherapyChemotherapy Drug AdministrationGynecologic Cancer PharmacotherapyOncology PharmacologyOvarian CancerOvarian Cancer PharmacotherapyToxicity ManagementChemotherapy PharmacodynamicsOvarian Cancer ChemotherapyOvarian Cancer Clinical TrialsOvarian Cancer TreatmentPartial Response AssessmentPhase Ii InvestigationStable Disease AssessmentStudy Phase
A phase II study of flutamide was conducted in 24 patients with stage III and IV ovarian cancer who failed chemotherapy and who had measurable disease. Flutamide was administered at a dose of 100 mg three times daily continuously until evidence of progression. Partial response observed in 1 of the 23 evaluable patients (4.3%) lasted 3 months. Two patients had stable disease (8.7%) for 7 and 8 months. The remaining 20 patients had progression of disease within 3 months. Toxicity was mild.